ZAI LAB

zai-lab-logo

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the C... hinese market. Leveraging their teamโ€™s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partnerโ€™s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.

#SimilarOrganizations #People #Financial #Event #Website #More

ZAI LAB

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2014-01-01

Address:
Shanghai, Shanghai, China

Country:
China

Website Url:
http://www.zailaboratory.com

Total Employee:
1001+

Status:
Active

Contact:
+86 21 6163 2588

Email Addresses:
[email protected]

Total Funding:
2.01 B USD

Technology used in webpage:
Domain Not Resolving Font Awesome IPv6 Google Universal Analytics Microsoft IIS 10 PHP 7 Amazon Route 53 ASP.NET 4.0 Microsoft Azure


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

i-mab-biopharma-logo

I-Mab Biopharma

I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.

icosavax-logo

Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

inovio-pharmaceuticals-logo

Inovio Pharmaceuticals

Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.

insilico-medicine-logo

Insilico Medicine

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

ocon-healthcare-logo

Ocon Healthcare

Our mission is to introduce innovative, high-quality an intrauterine drug-delivery technology to improve womenโ€™s health and quality of life

pharmnovo-logo

PharmNovo

PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe.

rome-therapeutics-logo

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

sai-life-sciences-logo

SAI Life Sciences

SAI Life Sciences delivers advanced Discovery, Contract Development and Manufacturing Solutions.

wuxi-apptec-logo

WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.


Current Advisors List

nisa-leung_image

Nisa Leung Member of the Board of Directors @ Zai Lab
Board_member
2014-01-01

Current Employees Featured

peter-huang_image

Peter Huang
Peter Huang Chief Scientific Officer @ Zai Lab
Chief Scientific Officer
2022-11-01

samantha-du_image

Samantha DU
Samantha DU Founder, CEO, & Chair @ Zai Lab
Founder, CEO, & Chair
2014-01-01

yongjiang-hei_image

Yongjiang Hei
Yongjiang Hei Chief Medical Officer, Oncology @ Zai Lab
Chief Medical Officer, Oncology
2018-08-01

yingyong-xu_image

Yingyong Xu
Yingyong Xu Vice President of Medical (Oncology) @ Zai Lab
Vice President of Medical (Oncology)
2022-09-01

not_available_image

Linda Liu
Linda Liu SVP, Biologics Discovery @ Zai Lab
SVP, Biologics Discovery
2022-02-01

harald-reinhart_image

Harald Reinhart
Harald Reinhart Chief Medical Officer, Autoimmune and Infectious Diseases @ Zai Lab
Chief Medical Officer, Autoimmune and Infectious Diseases

william-liang_image

William Liang
William Liang Chief Commercial Officer & President of Greater China @ Zai Lab
Chief Commercial Officer & President of Greater China
2018-06-01

Founder


samantha-du_image

Samantha DU

Stock Details


Company's stock symbol is NASDAQ:ZLAB

Investors List

vivo-capital_image

Vivo Capital

Vivo Capital investment in Series C - Zai Lab

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - Zai Lab

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Zai Lab

rock-springs-capital_image

Rock Springs Capital

Rock Springs Capital investment in Series C - Zai Lab

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series C - Zai Lab

sequoia-capital-china_image

Sequoia Capital China

Sequoia Capital China investment in Series B - Zai Lab

qiming-venture-partners_image

Qiming Venture Partners

Qiming Venture Partners investment in Series B - Zai Lab

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Zai Lab

advantech-capital_image

Advantech Capital

Advantech Capital investment in Series B - Zai Lab

tf-capital_image

TF Capital

TF Capital investment in Series B - Zai Lab

Investments List

Date Company Article Money raised
2016-12-01 dMed Zai Lab investment in Series A - dMed 8 M USD

Official Site Inspections

http://www.zailaboratory.com Semrush global rank: 2.91 M Semrush visits lastest month: 5.51 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Zai Lab"

About Zai Lab - Zai Lab

Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, autoimmune โ€ฆSee details»

What We Do - Zai Lab

Our strengths are the global experience within our organization in innovative drug R&D, our broad product portfolio and pipeline, and our track record of execution with speed and quality in clinical development, regulatory review, and โ€ฆSee details»

Investor Overview โ€“ Zai Lab Limited

2 days ago [email protected]. Lina Zhang, VP, Corporate Strategy and Capital Markets [email protected]. Media Inquiries Shaun Maccoun, Executive Director, Global Communications +1 (415) 317 โ€ฆSee details»

Zai Lab - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number +86 21 6163 2588 Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious โ€ฆSee details»

Zai Lab - LinkedIn

Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing โ€ฆSee details»

ZAI Lab Company Profile - Office Locations, Competitors ... - Craft

Oct 28, 2024 ZAI Lab has 5 employees across 7 locations and $266.72 m in annual revenue in FY 2023. See insights on ZAI Lab including office locations, competitors, revenue, financials, โ€ฆSee details»

Zai Lab Announces Third Quarter 2024 Financial Results and โ€ฆ

Sep 30, 2024 Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected โ€ฆSee details»

10 Years of Excellence - Zai Lab

Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company.See details»

Zai Lab Announces the Appointment of Josh Smiley as Chief โ€ฆ

Mar 15, 2022 Mr. Smiley began his career at Lilly in 1995, holding leadership positions across the organization culminating in his most recent role of Senior Vice President and Chief โ€ฆSee details»

Zai Lab - Overview, News & Similar companies | ZoomInfo.com

May 12, 2024 www.zailaboratory.com. Revenue $291.1 Million. Stock Symbol ZLAB. Industry Medical Devices & Equipment Manufacturing . Most Recent Scoops. May 13 2024. Earnings. โ€ฆSee details»

Zai Lab Announces Second Quarter 2024 Financial Results and โ€ฆ

Nov 27, 2024 Our efforts to build a stronger and more efficient organization, coupled with our innovative pipeline, position us for substantial topline growth and set us on the path to achieve โ€ฆSee details»

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel ...

Nov 21, 2024 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2024-- Zai Lab (โ€œZai Labโ€, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (โ€œPfizerโ€, NYSE: PFE) announced today โ€ฆSee details»

Zai Lab - LinkedIn

Zai Lab | 25,206 followers on LinkedIn. Delivering innovative, transformational outcomes to patients around the world | Zai Lab is an innovative, commercial-stage biopharmaceutical โ€ฆSee details»

Position Statements - Zai Lab

International Organization for Standardization (ISO) Supplier C ode of Conduct. Occupational Health and Safety Position Statement. U.S. Green Building Council (GBC) Zai Lab 2022 ESG โ€ฆSee details»

Zai Lab Announces First Quarter 2022 Financial ... - Zai Lab Limited

May 10, 2022 Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET. SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 10, 2022 (GLOBE โ€ฆSee details»

Zai Lab: Positioned For Growth In The Oncology Treatment Market

Ir.zailaboratory.com R&D expenses for 2022 saw a decrease when compared to the prior year. The reasoning behind this is lower upfront payments made for new licenses, indicating that the โ€ฆSee details»

Sustainability - Zai Lab

We commit to a healthier, more sustainable future. At Zai Lab, we understand and appreciate Environmental Protection, Social Responsibility and Corporate Governance (ESG) matters for โ€ฆSee details»

Zai Lab Announces Second Quarter 2021 Financial ... - Zai Lab โ€ฆ

Aug 9, 2021 Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT SHANGHAI and SAN FRANCISCO , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab โ€ฆSee details»

Zai Lab Presents Positive Results from Phase 3 PRIME ... - Zai Lab โ€ฆ

Mar 20, 2022 PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study โ€ฆSee details»

linkstock.net © 2022. All rights reserved